At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PMCB PharmaCyte Biotech, Inc.
Closed Independence Day 07-03 13:00:00 EDT
2.01
-0.05
-2.43%
盘后2.01
+0.000.00%
15:06 EDT
High2.12
Low2.01
Vol1.59K
Open2.12
D1 Closing2.06
Amplitude5.10%
Mkt Cap16.99M
Tradable Cap16.20M
Total Shares8.45M
T/O3.23K
T/O Rate0.02%
Tradable Shares8.06M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
PharmaCyte Biotech announces $7 million strategic investment in MYMD
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.